$MMI

Nadji Hessam sold $15K of MMI (indirect holdings)

Nadji Hessam (Chief Executive Officer) sold 500 indirectly-held shares of Marcus & Millichap, Inc. (MMI) at $30.38 on 2026-06-11.

Original reporting
SEC EDGAR · Nadji Hessam
Published Jun 12, 2026, 8:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 12, 2026, 8:52 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$MMI
Neutral
medium confidence
Mentioned
$MMI
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MMINeutralLow
01

Why it matters

Provides a fresh, primary-source datapoint on CEO selling activity; does not include company performance, guidance, or regulatory/contract developments.

02

Market read

Traders may monitor insider activity for sentiment, but this specific disclosure is small and lacks fundamental catalysts.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; without context on total holdings or prior patterns, signal quality is limited.

Relevance 3/10Novelty 8/10Timing: Filed 2026-06-12; transaction dated 2026-06-11

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for Marcus & Millichap, Inc.

Company-level read

Ticker impact

$MMINeutralMedium confidence
Context

CEO Nadji Hessam filed an SEC Form 4 selling 500 shares of Marcus & Millichap at $30.3850 on 2026-06-11 (indirect holdings).

Expected impact

Low near-term impact; any effect is likely sentiment-only and should be weighed against normal insider-sale patterns.

Evidence & confidence

The filing is a Form 4 insider sale (not a buy), but the disclosed size ($15.2k) is small and there is no 10b5-1 plan disclosed, reducing interpretive certainty.

Market effects

No clear sector read-through from a small, routine insider sale.

None indicated.

None indicated.

Counterpoint

Absence of a disclosed 10b5-1 plan could be interpreted as less “scheduled,” potentially increasing short-term skepticism despite the small dollar amount.

Key entities

  • Marcus & Millichap, Inc.

    Public RE brokerage company; subject of the Form 4 insider sale disclosure.

  • Nadji Hessam

    CEO and officer/director who sold 500 shares on 2026-06-11.

Related articles

$MMIMed

Marcus & Millichap Q2 Earnings Call Highlights

Marcus & Millichap (NYSE: MMI) reported Q2 financing revenue up 15% to $30 million, with transaction count up 17% to 480 and financing dollar volume up 5% to $4 billion. For the first half, financing revenue rose 29% to $57 million. Operating expenses rose to $201 million. Cash equivalents and marketable securities were $345 million. The board declared a $0.25 semiannual dividend and authorized further share repurchases.

$MMIMed

Marcus & Millichap, Inc. (MMI): Results of Operations and Financial Condition

Marcus & Millichap, Inc. (MMI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 er-q226earningsrelease.htm EX-99.1 Document MARCUS & MILLICHAP, INC. REPORTS PRELIMINARY RESULTS FOR SECOND QUARTER 2026 Revenue Grew 17.8% Compared to Second Quarter 2025 Net Income of $0.10 Per Diluted Share for Second Quarter 2026 CALABASAS, Calif., August 6, 2026 --

$MMIMed

Update on MMI and Further Investment

Crystal Amber Fund Limited said it invested a further $8.2 million in Morphic Medical Inc (MMI) since Feb 16, 2026, in three tranches at $0.48 per share, with the latest on July 31, 2026. The fund now holds 435,992,719 MMI shares (~97.9%). MMI reported FDA study pause removed, sites up to 40, US enrolment by early 2028, and Germany NUB status.